Design Therapeutics Stock Cash Flow From Operations
| DSGN Stock | USD 5.57 0.09 1.64% |
Design Therapeutics fundamentals help investors to digest information that contributes to Design Therapeutics' financial success or failures. It also enables traders to predict the movement of Design Stock. The fundamental analysis module provides a way to measure Design Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Design Therapeutics stock.
Design | Cash Flow From Operations |
Design Therapeutics Company Cash Flow From Operations Analysis
Design Therapeutics' Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current Design Therapeutics Cash Flow From Operations | (58.56 M) |
Most of Design Therapeutics' fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Design Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Design Cash Flow From Operations Driver Correlations
Understanding the fundamental principles of building solid financial models for Design Therapeutics is extremely important. It helps to project a fair market value of Design Stock properly, considering its historical fundamentals such as Cash Flow From Operations. Since Design Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Design Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Design Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
| Competition |
In accordance with the recently published financial statements, Design Therapeutics has (58.56 Million) in Cash Flow From Operations. This is 111.11% lower than that of the Biotechnology sector and 193.66% lower than that of the Health Care industry. The cash flow from operations for all United States stocks is 106.03% higher than that of the company.
Design Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Design Therapeutics' direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Design Therapeutics could also be used in its relative valuation, which is a method of valuing Design Therapeutics by comparing valuation metrics of similar companies.Design Therapeutics is currently under evaluation in cash flow from operations category among its peers.
Design Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Design Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Design Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Design Fundamentals
| Return On Equity | -0.18 | ||||
| Return On Asset | -0.14 | ||||
| Current Valuation | 58.73 M | ||||
| Shares Outstanding | 56.62 M | ||||
| Shares Owned By Insiders | 36.45 % | ||||
| Shares Owned By Institutions | 56.84 % | ||||
| Number Of Shares Shorted | 2.59 M | ||||
| Price To Book | 1.23 X | ||||
| Price To Sales | 22,642 X | ||||
| Gross Profit | (48.61 M) | ||||
| EBITDA | (66.33 M) | ||||
| Net Income | (66.86 M) | ||||
| Cash And Equivalents | 359.38 M | ||||
| Cash Per Share | 6.45 X | ||||
| Total Debt | 3.05 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 48.96 X | ||||
| Book Value Per Share | 4.46 X | ||||
| Cash Flow From Operations | (58.56 M) | ||||
| Short Ratio | 16.31 X | ||||
| Earnings Per Share | (0.85) X | ||||
| Target Price | 7.0 | ||||
| Number Of Employees | 54 | ||||
| Beta | 1.83 | ||||
| Market Capitalization | 310.28 M | ||||
| Total Asset | 289.64 M | ||||
| Retained Earnings | (177.63 M) | ||||
| Working Capital | 274.96 M | ||||
| Net Asset | 289.64 M |
About Design Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Design Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Design Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Design Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Design Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Design Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Design Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Design Stock
| 0.52 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.5 | KALV | Kalvista Pharmaceuticals | PairCorr |
| 0.49 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.49 | KTTA | Pasithea Therapeutics | PairCorr |
| 0.47 | INZY | Inozyme Pharma | PairCorr |
The ability to find closely correlated positions to Design Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Design Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Design Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Design Therapeutics to buy it.
The correlation of Design Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Design Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Design Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Design Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Design Therapeutics Piotroski F Score and Design Therapeutics Altman Z Score analysis. To learn how to invest in Design Stock, please use our How to Invest in Design Therapeutics guide.You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Design Therapeutics. If investors know Design will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Design Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.85) | Revenue Per Share 0.001 | Return On Assets (0.14) | Return On Equity (0.18) |
The market value of Design Therapeutics is measured differently than its book value, which is the value of Design that is recorded on the company's balance sheet. Investors also form their own opinion of Design Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Design Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Design Therapeutics' market value can be influenced by many factors that don't directly affect Design Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Design Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Design Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Design Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.